Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Stefan Koehrer"'
Autor:
Tamara Kempter, Paulina Richter-Pechanska, Katarzyna Michel, Tobias Rausch, Büşra Erarslan-Uysal, Cornelia Eckert, Martin Zimmermann, Martin Stanulla, Martin Schrappe, Gunnar Cario, Renate Kirschner-Schwabe, Stefan Koehrer, Jan Korbel, Joachim Kunz, Andreas E Kulozik
Publikováno v:
HemaSphere, Vol 7, p e9493074 (2023)
Externí odkaz:
https://doaj.org/article/77ee918485564004bb875af4218b482e
Autor:
Andrew J. Steele, Jan A. Burger, Greg P. Coffey, Francesco Forconi, Graham Packham, Freda K. Stevenson, Jonathan C. Strefford, Anjali Pandey, Pamela B. Conley, Peter W.M. Johnson, Andrew Davies, Lindsay D. Smith, Jack Parnell, Alice Hayman, Sarah Wilmore, Marta Larrayoz, Rachel C. Dobson, Stefan Koehrer, Matthew D. Blunt
Supplementary methods and Figures Supplementary Figure 1. Effect of cerdulatinib on Immobilised anti-IgM mediated signaling Supplementary Figure 2. Effect of cerdulatinib on soluble anti-IgM mediated signaling Supplementary Figure 3. Effect of cerdul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a468e825532cc2770eba48a39c5394f7
https://doi.org/10.1158/1078-0432.22463541
https://doi.org/10.1158/1078-0432.22463541
Autor:
Andrew J. Steele, Jan A. Burger, Greg P. Coffey, Francesco Forconi, Graham Packham, Freda K. Stevenson, Jonathan C. Strefford, Anjali Pandey, Pamela B. Conley, Peter W.M. Johnson, Andrew Davies, Lindsay D. Smith, Jack Parnell, Alice Hayman, Sarah Wilmore, Marta Larrayoz, Rachel C. Dobson, Stefan Koehrer, Matthew D. Blunt
Purpose: B-cell receptor (BCR)–associated kinase inhibitors, such as ibrutinib, have revolutionized the treatment of chronic lymphocytic leukemia (CLL). However, these agents are not curative, and resistance is already emerging in a proportion of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65982893f3a24771c803dc31b3ed3e60
https://doi.org/10.1158/1078-0432.c.6525432
https://doi.org/10.1158/1078-0432.c.6525432
Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK
Autor:
Betty Y. Chang, R. Eric Davis, Zhiqiang Wang, Christian Hurtz, Ekaterina Kim, Jan A. Burger, Sriram Balasubramanian, Stefan Koehrer, Markus Müschen
Publikováno v:
Blood. 129:1155-1165
Targeting B-cell receptor (BCR) signaling is a successful therapeutic strategy in mature B-cell malignancies. Precursor BCR (pre-BCR) signaling, which is critical during normal B lymphopoiesis, also plays an important role in pre-BCR+ B cell acute ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e7620ee152e514969f6034e414cee29
https://doi.org/10.1182/blood-2016-06-722900
https://doi.org/10.1182/blood-2016-06-722900
Autor:
Shubhchintan Randhawa, Jan A. Burger, Mariela Sivina, Richard E. Davis, Dipanjan Ghosh, Marina Konopleva, Stefan Koehrer, Amnon Peled, Markus Müschen, Byung Sik Cho
Publikováno v:
British Journal of Haematology. 174:425-436
B cell acute lymphoblastic leukaemia (B-ALL) cells express high levels of CXCR4 chemokine receptors for homing and retention within the marrow microenvironment. Bone marrow stromal cells (BMSC) secrete CXCL12, the ligand for CXCR4, and protect B-ALL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::139f890332e6d65c827e883af0eced2f
https://doi.org/10.1111/bjh.14075
https://doi.org/10.1111/bjh.14075
Autor:
Anjali Pandey, Stefan Koehrer, Jonathan C. Strefford, Andrew J. Steele, Matthew D. Blunt, Alice Hayman, Andrew Davies, Greg Coffey, Freda K. Stevenson, Francesco Forconi, Pamela B. Conley, Sarah Wilmore, Jack Parnell, Lindsay D. Smith, Peter Johnson, Jan A. Burger, Marta Larrayoz, Rachel Dobson, Graham Packham
Purpose: B-cell receptor (BCR)–associated kinase inhibitors, such as ibrutinib, have revolutionized the treatment of chronic lymphocytic leukemia (CLL). However, these agents are not curative, and resistance is already emerging in a proportion of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55792179012f48052b8105e899855173
https://eprints.soton.ac.uk/401087/
https://eprints.soton.ac.uk/401087/
Autor:
Ekaterina, Kim, Christian, Hurtz, Stefan, Koehrer, Zhiqiang, Wang, Sriram, Balasubramanian, Betty Y, Chang, Markus, Müschen, R Eric, Davis, Jan A, Burger
Publikováno v:
Blood. 129(9)
Targeting B-cell receptor (BCR) signaling is a successful therapeutic strategy in mature B-cell malignancies. Precursor BCR (pre-BCR) signaling, which is critical during normal B lymphopoiesis, also plays an important role in pre-BCR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::15e7f82f9ff492944198f64869e77dc3
https://pubmed.ncbi.nlm.nih.gov/28254821
https://pubmed.ncbi.nlm.nih.gov/28254821
Autor:
Stefan, Koehrer, Jan A, Burger
Publikováno v:
Clinical advances in hematologyoncology : HO. 14(1)
B-cell receptor (BCR) signaling has emerged as a key pathway for the expansion of neoplastic B-cell clones in several B-cell malignancies. The mechanisms that activate BCR signaling differ substantially among subtypes of B-cell lymphoma and leukemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fae0f509b92f33ee46570f1fbe0fdb08
https://pubmed.ncbi.nlm.nih.gov/27057669
https://pubmed.ncbi.nlm.nih.gov/27057669
Autor:
Eva Zebedin, Stefan Koehrer, Sabine Strommer, Thorsten Fuereder, Volker Wacheck, Johannes Werzowa, Daniel Cejka
Publikováno v:
Journal of Investigative Dermatology. 131(2):495-503
The phosphatidyl inositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway has been shown to be involved in the development of melanoma. PI-103 is a kinase inhibitor blocking PI3K class IA and mTOR complex 1 and 2. Here, we studied the effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::041474aebbb4073d0fdd195373bd5973
Autor:
Richard Crevenna, Agnes Jaeger-Lansky, Thorsten Fuereder, Stefan Koehrer, Doris Hoeflmayer, Sabine Strommer, Matthias Preusser, Daniel Cejka, Volker Wacheck
Publikováno v:
Cancer Letters. 296:249-256
VEGF receptor blockage has been reported to increase serum VEGF. We hypothesized that mTOR inhibition by everolimus counteracts VEGF induction by sunitinib resulting in an improved anti-tumor activity of sunitinib. In vitro, sunitinib in combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b49aba7c933856658107dae576c49ae9
https://doi.org/10.1016/j.canlet.2010.04.015
https://doi.org/10.1016/j.canlet.2010.04.015